<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75537</article-id><article-id pub-id-type="doi">10.7554/eLife.75537</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-156787"><name><surname>Hawman</surname><given-names>David W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8233-8176</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-213841"><name><surname>Meade-White</surname><given-names>Kimberly</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263238"><name><surname>Archer</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-213842"><name><surname>Leventhal</surname><given-names>Shanna S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263239"><name><surname>Wilson</surname><given-names>Drew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263240"><name><surname>Shaia</surname><given-names>Carl</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263241"><name><surname>Randall</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263242"><name><surname>Khandhar</surname><given-names>Amit P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-269982"><name><surname>Krieger</surname><given-names>Kyle</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241327"><name><surname>Hsiang</surname><given-names>Tien-Ying</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-9390"><name><surname>Gale</surname><given-names>Michael</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-263243"><name><surname>Berglund</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-263244"><name><surname>Fuller</surname><given-names>Deborah Heydenburg</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-152984"><name><surname>Feldmann</surname><given-names>Heinz</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9448-8227</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-263227"><name><surname>Erasmus</surname><given-names>Jesse</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1612-2697</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Virology</institution>, <institution>National Institute of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Hamilton</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>HDT Bio</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Division of Intramural Research</institution>, <institution>National Institute of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Hamilton</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Microbiology</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Immunology</institution>, <institution>The University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Department of Immunology</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-61967"><name><surname>Kurosaki</surname><given-names>Tomohiro</given-names></name><role>Reviewing editor</role><aff><institution>Osaka University</institution>, <country>Japan</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>david.hawman@nih.gov</email> (DH);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>feldmannh@niaid.nih.gov</email> (HF);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>jesse.erasmus@hdt.bio</email> (JE);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>02</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e75537</elocation-id><history><date date-type="received"><day>13</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>17</day><month>02</month><year>2022</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75537-v1.pdf"/><abstract><p>Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late-2021 with resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants of concern (VoC) and evidence that existing vaccines that were designed to protect from the original strains of SARS-CoV-2 may have reduced potency for protection from infection against these VoC is driving continued development of second generation vaccines that can protect against multiple VoC. In this report, we evaluated an alphavirus-based replicating RNA vaccine expressing Spike proteins from the original SARS-CoV-2 Alpha strain and recent VoCs delivered <italic>in vivo</italic> via a lipid inorganic nanoparticle. Vaccination of both mice and Syrian Golden hamsters showed that vaccination induced potent neutralizing titers against each homologous VoC but reduced neutralization against heterologous challenges. Vaccinated hamsters challenged with homologous SARS-CoV2 variants exhibited complete protection from infection. In addition, vaccinated hamsters challenged with heterologous SARS-CoV-2 variants exhibited significantly reduced shedding of infectious virus. Our data demonstrate that this vaccine platform can be updated to target emergent VoCs, elicits significant protective immunity against SARS-CoV2 variants and supports continued development of this platform.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Gale</surname><given-names>Michael</given-names><suffix>Jr</suffix></name><name><surname>Erasmus</surname><given-names>Jesse</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hawman</surname><given-names>David W</given-names></name><name><surname>Meade-White</surname><given-names>Kimberly</given-names></name><name><surname>Leventhal</surname><given-names>Shanna S</given-names></name><name><surname>Wilson</surname><given-names>Drew</given-names></name><name><surname>Shaia</surname><given-names>Carl</given-names></name><name><surname>Feldmann</surname><given-names>Heinz</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Jacob Archer, is a consultant for InBios.</p></fn><fn fn-type="conflict" id="conf3"><p>Amit P Khandhar, has equity interest in HDT Bio. Is a co-inventors on U.S. patent application no. 62/993,307 Compositions and methods for delivery of RNA&quot; pertaining to the LION formulation.&quot;.</p></fn><fn fn-type="conflict" id="conf4"><p>Michael Gale, has equity interest in HDT Bio..</p></fn><fn fn-type="conflict" id="conf5"><p>Peter Berglund, has equity interest in HDT Bio. Is a consultant for Arcturus, Sensei, and Next Phase..</p></fn><fn fn-type="conflict" id="conf6"><p>Deborah Heydenburg Fuller, has equity interest in HDT Bio. Is a consultant for Gerson Lehrman Group, Orlance, Abacus Bioscience, Neoleukin Therapeutics..</p></fn><fn fn-type="conflict" id="conf7"><p>Jesse Erasmus, has equity interest in HDT Bio. Is a consultant for InBios. Is a co-inventors on U.S. patent application no. 62/993,307 Compositions and methods for delivery of RNA&quot; pertaining to the LION formulation.&quot;.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were approved by the corresponding institutional animal care and use committee and performed by experienced personnel under veterinary oversight (Protocol #2020-63).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the figures and supporting files</p></sec><supplementary-material><ext-link xlink:href="elife-75537-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>